AcelRx Pharmaceuticals: Q1 Earnings Insights

Shares of AcelRx Pharmaceuticals ACRX decreased in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 60.00% year over year to ($0.08), which were in line with the estimate of ($0.08).

Revenue of $511,000 up by 32.38% year over year, which missed the estimate of $1,060,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 17, 2021

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/406/41005

Recent Stock Performance

Company's 52-week high was at $2.94

Company's 52-week low was at $1.01

Price action over last quarter: down 40.86%

Company Overview

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!